Glenmark Pharma Rating Upgraded to IND AA+ After Balance-Sheet Turnaround

FY26 EBITDA rose to ₹45,724 million from ₹23,514 million, while EBITDA margin expanded to 26.9% from 17.7%.
Glenmark ended FY26 in a net cash position with zero gross debt, while operating cash flow turned positive at ₹32,800 million.

Reader Takeaway: Licensing proceeds strengthened credit metrics, but sustaining margins after one-time income remains the key test.

What just happened

India Ratings and Research upgraded Glenmark Pharmaceuticals' long-term bank loan rating to IND AA+ from IND AA and retained a Stable outlook.

The short-term rating was affirmed at IND A1+.

The main driver was better financial visibility following Glenmark's exclusive global licensing agreement for ISB 2001 with AbbVie, signed in July 2025.

Glenmark recognised $560 million of revenue from the deal in FY26. Another $140 million is expected in two equal instalments of $70 million each in FY27 and FY28.

Why this matters

The licensing income has materially altered Glenmark's balance sheet and cash-generation profile.

Consolidated revenue rose to ₹169,825 million in FY26 from ₹133,217 million in FY25. EBITDA increased to ₹45,724 million from ₹23,514 million, while the EBITDA margin expanded to 26.9% from 17.7%.

Total adjusted debt dropped sharply to ₹5,935 million from ₹24,727 million. Net adjusted leverage improved to negative 0.1 times from 0.3 times, while gross adjusted coverage strengthened to 21.9 times from 11.4 times.

Cash flow improves sharply

Cash flow from operations swung to a positive ₹32,800 million in FY26 from a negative ₹9,800 million in FY25.

Free cash flow also turned positive at ₹17,800 million. The company ended FY26 with zero gross debt and does not have scheduled debt repayments in FY27 or FY28.

The licensing proceeds also made Ichnos Glenmark Innovation more self-funded, reducing its dependence on the parent for capital support.

What changes now

Management expects FY27 revenue of ₹170 billion to ₹180 billion, with an EBITDA margin of 21% to 22%.

Margins are expected to improve further in FY28 and FY29, supported by differentiated product launches, R&D spending of 7% to 8% of sales, a ramp-up in Ryaltris, a continued focus on the higher-margin India business and better operating leverage in Europe and Latin America.

The US business is expected to return to double-digit sales growth from FY27, supported by new launches and commercialisation of injectables and respiratory products.

Risks to watch

The key question is how much of FY26's stronger profitability can be sustained once the one-time licensing impact normalises.

Regulatory scrutiny from the US Food and Drug Administration remains a monitorable risk, while price controls affect about 17% of Glenmark's India sales.

Execution in the US and India businesses will also matter as investors assess whether core operations can support the stronger credit profile without relying on exceptional licensing income.

What to track next

Investors should watch FY27 revenue against the ₹170-180 billion guidance range, EBITDA margin delivery at 21%-22%, debt discipline, Ryaltris growth and the pace of recovery in the US and India businesses.